# Research Progress of Biosensing Technology in the Detection of Creatine Kinase Isoenzyme MB

## TL;DR

This paper reviews biosensing technology for detecting a heart attack biomarker called CK-MB, aiming to improve early diagnosis and patient outcomes.

## Contribution

The paper highlights biosensing as a novel, portable solution for accurate and rapid CK-MB detection.

## Key findings

- CK-MB is a key biomarker that rises rapidly after heart injury and has high specificity for monitoring heart attacks.
- Traditional CK-MB detection methods are limited by false positives, large blood samples, and complex procedures.
- Biosensors offer a low-cost, sensitive, and portable alternative for point-of-care CK-MB testing.

## Abstract

Although significant progress has been made in the global medical level, cardiovascular diseases still pose a serious threat to human life and health. Among many cardiovascular diseases, acute myocardial infarction (AMI) is particularly severe. If not treated in a timely manner, it may lead to serious consequences such as cardiac arrest and sudden death. Early diagnosis of myocardial infarction (MI) is an important means of preventing and controlling the mortality rate of AMI. Creatine kinase isoenzyme (CK-MB) is a key biomarker of MI. It rises rapidly within 2 h after myocardial injury, reaches its peak at 24 h, and returns to normal at 72 h. Furthermore, CK-MB has a high specificity in monitoring secondary MI. Therefore, the early, real-time, and accurate detection of CK-MB is of great significance for the prevention, diagnosis, and prognosis of AMI. Conventional CK-MB detection methods have problems such as false positive elevation, large blood sampling volume, long time consumption, and complex operation, making it difficult to meet the needs of point-of-care testing (POCT). Biosensor technology, with its low cost, high sensitivity, and portability, offers a promising solution for point-of-care CK-MB testing, thereby greatly aiding AMI diagnosis.